Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor
This phase I study evaluated selective JAK2 inhibitor XL019 in 30 patients with myelofibrosis. The initial dose cohorts were 100, 200, and 300mg orally on days 1–21 of a 28-day cycle. Central and/or peripheral neurotoxicity developed in all patients. Subsequently, patients were treated on lower dose...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Verstovsek, Srdan [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2014transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
7 |
|---|
| Übergeordnetes Werk: |
Enthalten in: N - Li, Danyang ELSEVIER, 2019, clinical and laboratory studies, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:38 ; year:2014 ; number:3 ; pages:316-322 ; extent:7 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.leukres.2013.12.006 |
|---|
| Katalog-ID: |
ELV017314542 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV017314542 | ||
| 003 | DE-627 | ||
| 005 | 20230625122028.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180602s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.leukres.2013.12.006 |2 doi | |
| 028 | 5 | 2 | |a GBVA2014003000025.pica |
| 035 | |a (DE-627)ELV017314542 | ||
| 035 | |a (ELSEVIER)S0145-2126(13)00425-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 333.7 |a 610 |q VZ |
| 084 | |a 43.12 |2 bkl | ||
| 084 | |a 43.13 |2 bkl | ||
| 084 | |a 44.13 |2 bkl | ||
| 100 | 1 | |a Verstovsek, Srdan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor |
| 264 | 1 | |c 2014transfer abstract | |
| 300 | |a 7 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a This phase I study evaluated selective JAK2 inhibitor XL019 in 30 patients with myelofibrosis. The initial dose cohorts were 100, 200, and 300mg orally on days 1–21 of a 28-day cycle. Central and/or peripheral neurotoxicity developed in all patients. Subsequently, patients were treated on lower doses; neurotoxicity was again observed, leading to study termination. Peripheral neuropathy resolved in 50%, and central neurotoxicity in all patients within months after therapy cessation. Myelosuppression was minimal. The terminal half-life of XL019 was approximately 21h, with steady state reached by Day 8. International Working Group defined responses were seen in three (10%) patients. | ||
| 520 | |a This phase I study evaluated selective JAK2 inhibitor XL019 in 30 patients with myelofibrosis. The initial dose cohorts were 100, 200, and 300mg orally on days 1–21 of a 28-day cycle. Central and/or peripheral neurotoxicity developed in all patients. Subsequently, patients were treated on lower doses; neurotoxicity was again observed, leading to study termination. Peripheral neuropathy resolved in 50%, and central neurotoxicity in all patients within months after therapy cessation. Myelosuppression was minimal. The terminal half-life of XL019 was approximately 21h, with steady state reached by Day 8. International Working Group defined responses were seen in three (10%) patients. | ||
| 650 | 7 | |a Myelofibrosis |2 Elsevier | |
| 650 | 7 | |a Inhibitor |2 Elsevier | |
| 650 | 7 | |a Mutation |2 Elsevier | |
| 650 | 7 | |a JAK2 |2 Elsevier | |
| 650 | 7 | |a XL019 |2 Elsevier | |
| 700 | 1 | |a Tam, Constantine S. |4 oth | |
| 700 | 1 | |a Wadleigh, Martha |4 oth | |
| 700 | 1 | |a Sokol, Lubomir |4 oth | |
| 700 | 1 | |a Smith, Catherine C. |4 oth | |
| 700 | 1 | |a Bui, Lynne A. |4 oth | |
| 700 | 1 | |a Song, Chunyan |4 oth | |
| 700 | 1 | |a Clary, Douglas O. |4 oth | |
| 700 | 1 | |a Olszynski, Patrycja |4 oth | |
| 700 | 1 | |a Cortes, Jorge |4 oth | |
| 700 | 1 | |a Kantarjian, Hagop |4 oth | |
| 700 | 1 | |a Shah, Neil P. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Li, Danyang ELSEVIER |t N |d 2019 |d clinical and laboratory studies |g Amsterdam [u.a.] |w (DE-627)ELV002185202 |
| 773 | 1 | 8 | |g volume:38 |g year:2014 |g number:3 |g pages:316-322 |g extent:7 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.leukres.2013.12.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-GGO | ||
| 936 | b | k | |a 43.12 |j Umweltchemie |q VZ |
| 936 | b | k | |a 43.13 |j Umwelttoxikologie |q VZ |
| 936 | b | k | |a 44.13 |j Medizinische Ökologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 38 |j 2014 |e 3 |h 316-322 |g 7 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
s v sv |
|---|---|
| matchkey_str |
verstovseksrdantamconstantineswadleighma:2014----:hsivlainfl1aoaptnadeet |
| hierarchy_sort_str |
2014transfer abstract |
| bklnumber |
43.12 43.13 44.13 |
| publishDate |
2014 |
| allfields |
10.1016/j.leukres.2013.12.006 doi GBVA2014003000025.pica (DE-627)ELV017314542 (ELSEVIER)S0145-2126(13)00425-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 333.7 610 VZ 43.12 bkl 43.13 bkl 44.13 bkl Verstovsek, Srdan verfasserin aut Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor 2014transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier This phase I study evaluated selective JAK2 inhibitor XL019 in 30 patients with myelofibrosis. The initial dose cohorts were 100, 200, and 300mg orally on days 1–21 of a 28-day cycle. Central and/or peripheral neurotoxicity developed in all patients. Subsequently, patients were treated on lower doses; neurotoxicity was again observed, leading to study termination. Peripheral neuropathy resolved in 50%, and central neurotoxicity in all patients within months after therapy cessation. Myelosuppression was minimal. The terminal half-life of XL019 was approximately 21h, with steady state reached by Day 8. International Working Group defined responses were seen in three (10%) patients. This phase I study evaluated selective JAK2 inhibitor XL019 in 30 patients with myelofibrosis. The initial dose cohorts were 100, 200, and 300mg orally on days 1–21 of a 28-day cycle. Central and/or peripheral neurotoxicity developed in all patients. Subsequently, patients were treated on lower doses; neurotoxicity was again observed, leading to study termination. Peripheral neuropathy resolved in 50%, and central neurotoxicity in all patients within months after therapy cessation. Myelosuppression was minimal. The terminal half-life of XL019 was approximately 21h, with steady state reached by Day 8. International Working Group defined responses were seen in three (10%) patients. Myelofibrosis Elsevier Inhibitor Elsevier Mutation Elsevier JAK2 Elsevier XL019 Elsevier Tam, Constantine S. oth Wadleigh, Martha oth Sokol, Lubomir oth Smith, Catherine C. oth Bui, Lynne A. oth Song, Chunyan oth Clary, Douglas O. oth Olszynski, Patrycja oth Cortes, Jorge oth Kantarjian, Hagop oth Shah, Neil P. oth Enthalten in Elsevier Science Li, Danyang ELSEVIER N 2019 clinical and laboratory studies Amsterdam [u.a.] (DE-627)ELV002185202 volume:38 year:2014 number:3 pages:316-322 extent:7 https://doi.org/10.1016/j.leukres.2013.12.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-GGO 43.12 Umweltchemie VZ 43.13 Umwelttoxikologie VZ 44.13 Medizinische Ökologie VZ AR 38 2014 3 316-322 7 045F 610 |
| spelling |
10.1016/j.leukres.2013.12.006 doi GBVA2014003000025.pica (DE-627)ELV017314542 (ELSEVIER)S0145-2126(13)00425-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 333.7 610 VZ 43.12 bkl 43.13 bkl 44.13 bkl Verstovsek, Srdan verfasserin aut Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor 2014transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier This phase I study evaluated selective JAK2 inhibitor XL019 in 30 patients with myelofibrosis. The initial dose cohorts were 100, 200, and 300mg orally on days 1–21 of a 28-day cycle. Central and/or peripheral neurotoxicity developed in all patients. Subsequently, patients were treated on lower doses; neurotoxicity was again observed, leading to study termination. Peripheral neuropathy resolved in 50%, and central neurotoxicity in all patients within months after therapy cessation. Myelosuppression was minimal. The terminal half-life of XL019 was approximately 21h, with steady state reached by Day 8. International Working Group defined responses were seen in three (10%) patients. This phase I study evaluated selective JAK2 inhibitor XL019 in 30 patients with myelofibrosis. The initial dose cohorts were 100, 200, and 300mg orally on days 1–21 of a 28-day cycle. Central and/or peripheral neurotoxicity developed in all patients. Subsequently, patients were treated on lower doses; neurotoxicity was again observed, leading to study termination. Peripheral neuropathy resolved in 50%, and central neurotoxicity in all patients within months after therapy cessation. Myelosuppression was minimal. The terminal half-life of XL019 was approximately 21h, with steady state reached by Day 8. International Working Group defined responses were seen in three (10%) patients. Myelofibrosis Elsevier Inhibitor Elsevier Mutation Elsevier JAK2 Elsevier XL019 Elsevier Tam, Constantine S. oth Wadleigh, Martha oth Sokol, Lubomir oth Smith, Catherine C. oth Bui, Lynne A. oth Song, Chunyan oth Clary, Douglas O. oth Olszynski, Patrycja oth Cortes, Jorge oth Kantarjian, Hagop oth Shah, Neil P. oth Enthalten in Elsevier Science Li, Danyang ELSEVIER N 2019 clinical and laboratory studies Amsterdam [u.a.] (DE-627)ELV002185202 volume:38 year:2014 number:3 pages:316-322 extent:7 https://doi.org/10.1016/j.leukres.2013.12.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-GGO 43.12 Umweltchemie VZ 43.13 Umwelttoxikologie VZ 44.13 Medizinische Ökologie VZ AR 38 2014 3 316-322 7 045F 610 |
| allfields_unstemmed |
10.1016/j.leukres.2013.12.006 doi GBVA2014003000025.pica (DE-627)ELV017314542 (ELSEVIER)S0145-2126(13)00425-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 333.7 610 VZ 43.12 bkl 43.13 bkl 44.13 bkl Verstovsek, Srdan verfasserin aut Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor 2014transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier This phase I study evaluated selective JAK2 inhibitor XL019 in 30 patients with myelofibrosis. The initial dose cohorts were 100, 200, and 300mg orally on days 1–21 of a 28-day cycle. Central and/or peripheral neurotoxicity developed in all patients. Subsequently, patients were treated on lower doses; neurotoxicity was again observed, leading to study termination. Peripheral neuropathy resolved in 50%, and central neurotoxicity in all patients within months after therapy cessation. Myelosuppression was minimal. The terminal half-life of XL019 was approximately 21h, with steady state reached by Day 8. International Working Group defined responses were seen in three (10%) patients. This phase I study evaluated selective JAK2 inhibitor XL019 in 30 patients with myelofibrosis. The initial dose cohorts were 100, 200, and 300mg orally on days 1–21 of a 28-day cycle. Central and/or peripheral neurotoxicity developed in all patients. Subsequently, patients were treated on lower doses; neurotoxicity was again observed, leading to study termination. Peripheral neuropathy resolved in 50%, and central neurotoxicity in all patients within months after therapy cessation. Myelosuppression was minimal. The terminal half-life of XL019 was approximately 21h, with steady state reached by Day 8. International Working Group defined responses were seen in three (10%) patients. Myelofibrosis Elsevier Inhibitor Elsevier Mutation Elsevier JAK2 Elsevier XL019 Elsevier Tam, Constantine S. oth Wadleigh, Martha oth Sokol, Lubomir oth Smith, Catherine C. oth Bui, Lynne A. oth Song, Chunyan oth Clary, Douglas O. oth Olszynski, Patrycja oth Cortes, Jorge oth Kantarjian, Hagop oth Shah, Neil P. oth Enthalten in Elsevier Science Li, Danyang ELSEVIER N 2019 clinical and laboratory studies Amsterdam [u.a.] (DE-627)ELV002185202 volume:38 year:2014 number:3 pages:316-322 extent:7 https://doi.org/10.1016/j.leukres.2013.12.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-GGO 43.12 Umweltchemie VZ 43.13 Umwelttoxikologie VZ 44.13 Medizinische Ökologie VZ AR 38 2014 3 316-322 7 045F 610 |
| allfieldsGer |
10.1016/j.leukres.2013.12.006 doi GBVA2014003000025.pica (DE-627)ELV017314542 (ELSEVIER)S0145-2126(13)00425-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 333.7 610 VZ 43.12 bkl 43.13 bkl 44.13 bkl Verstovsek, Srdan verfasserin aut Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor 2014transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier This phase I study evaluated selective JAK2 inhibitor XL019 in 30 patients with myelofibrosis. The initial dose cohorts were 100, 200, and 300mg orally on days 1–21 of a 28-day cycle. Central and/or peripheral neurotoxicity developed in all patients. Subsequently, patients were treated on lower doses; neurotoxicity was again observed, leading to study termination. Peripheral neuropathy resolved in 50%, and central neurotoxicity in all patients within months after therapy cessation. Myelosuppression was minimal. The terminal half-life of XL019 was approximately 21h, with steady state reached by Day 8. International Working Group defined responses were seen in three (10%) patients. This phase I study evaluated selective JAK2 inhibitor XL019 in 30 patients with myelofibrosis. The initial dose cohorts were 100, 200, and 300mg orally on days 1–21 of a 28-day cycle. Central and/or peripheral neurotoxicity developed in all patients. Subsequently, patients were treated on lower doses; neurotoxicity was again observed, leading to study termination. Peripheral neuropathy resolved in 50%, and central neurotoxicity in all patients within months after therapy cessation. Myelosuppression was minimal. The terminal half-life of XL019 was approximately 21h, with steady state reached by Day 8. International Working Group defined responses were seen in three (10%) patients. Myelofibrosis Elsevier Inhibitor Elsevier Mutation Elsevier JAK2 Elsevier XL019 Elsevier Tam, Constantine S. oth Wadleigh, Martha oth Sokol, Lubomir oth Smith, Catherine C. oth Bui, Lynne A. oth Song, Chunyan oth Clary, Douglas O. oth Olszynski, Patrycja oth Cortes, Jorge oth Kantarjian, Hagop oth Shah, Neil P. oth Enthalten in Elsevier Science Li, Danyang ELSEVIER N 2019 clinical and laboratory studies Amsterdam [u.a.] (DE-627)ELV002185202 volume:38 year:2014 number:3 pages:316-322 extent:7 https://doi.org/10.1016/j.leukres.2013.12.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-GGO 43.12 Umweltchemie VZ 43.13 Umwelttoxikologie VZ 44.13 Medizinische Ökologie VZ AR 38 2014 3 316-322 7 045F 610 |
| allfieldsSound |
10.1016/j.leukres.2013.12.006 doi GBVA2014003000025.pica (DE-627)ELV017314542 (ELSEVIER)S0145-2126(13)00425-6 DE-627 ger DE-627 rakwb eng 610 610 DE-600 333.7 610 VZ 43.12 bkl 43.13 bkl 44.13 bkl Verstovsek, Srdan verfasserin aut Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor 2014transfer abstract 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier This phase I study evaluated selective JAK2 inhibitor XL019 in 30 patients with myelofibrosis. The initial dose cohorts were 100, 200, and 300mg orally on days 1–21 of a 28-day cycle. Central and/or peripheral neurotoxicity developed in all patients. Subsequently, patients were treated on lower doses; neurotoxicity was again observed, leading to study termination. Peripheral neuropathy resolved in 50%, and central neurotoxicity in all patients within months after therapy cessation. Myelosuppression was minimal. The terminal half-life of XL019 was approximately 21h, with steady state reached by Day 8. International Working Group defined responses were seen in three (10%) patients. This phase I study evaluated selective JAK2 inhibitor XL019 in 30 patients with myelofibrosis. The initial dose cohorts were 100, 200, and 300mg orally on days 1–21 of a 28-day cycle. Central and/or peripheral neurotoxicity developed in all patients. Subsequently, patients were treated on lower doses; neurotoxicity was again observed, leading to study termination. Peripheral neuropathy resolved in 50%, and central neurotoxicity in all patients within months after therapy cessation. Myelosuppression was minimal. The terminal half-life of XL019 was approximately 21h, with steady state reached by Day 8. International Working Group defined responses were seen in three (10%) patients. Myelofibrosis Elsevier Inhibitor Elsevier Mutation Elsevier JAK2 Elsevier XL019 Elsevier Tam, Constantine S. oth Wadleigh, Martha oth Sokol, Lubomir oth Smith, Catherine C. oth Bui, Lynne A. oth Song, Chunyan oth Clary, Douglas O. oth Olszynski, Patrycja oth Cortes, Jorge oth Kantarjian, Hagop oth Shah, Neil P. oth Enthalten in Elsevier Science Li, Danyang ELSEVIER N 2019 clinical and laboratory studies Amsterdam [u.a.] (DE-627)ELV002185202 volume:38 year:2014 number:3 pages:316-322 extent:7 https://doi.org/10.1016/j.leukres.2013.12.006 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-GGO 43.12 Umweltchemie VZ 43.13 Umwelttoxikologie VZ 44.13 Medizinische Ökologie VZ AR 38 2014 3 316-322 7 045F 610 |
| language |
English |
| source |
Enthalten in N Amsterdam [u.a.] volume:38 year:2014 number:3 pages:316-322 extent:7 |
| sourceStr |
Enthalten in N Amsterdam [u.a.] volume:38 year:2014 number:3 pages:316-322 extent:7 |
| format_phy_str_mv |
Article |
| bklname |
Umweltchemie Umwelttoxikologie Medizinische Ökologie |
| institution |
findex.gbv.de |
| topic_facet |
Myelofibrosis Inhibitor Mutation JAK2 XL019 |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
N |
| authorswithroles_txt_mv |
Verstovsek, Srdan @@aut@@ Tam, Constantine S. @@oth@@ Wadleigh, Martha @@oth@@ Sokol, Lubomir @@oth@@ Smith, Catherine C. @@oth@@ Bui, Lynne A. @@oth@@ Song, Chunyan @@oth@@ Clary, Douglas O. @@oth@@ Olszynski, Patrycja @@oth@@ Cortes, Jorge @@oth@@ Kantarjian, Hagop @@oth@@ Shah, Neil P. @@oth@@ |
| publishDateDaySort_date |
2014-01-01T00:00:00Z |
| hierarchy_top_id |
ELV002185202 |
| dewey-sort |
3610 |
| id |
ELV017314542 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV017314542</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625122028.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.leukres.2013.12.006</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014003000025.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV017314542</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0145-2126(13)00425-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">333.7</subfield><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">43.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">43.13</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.13</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Verstovsek, Srdan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This phase I study evaluated selective JAK2 inhibitor XL019 in 30 patients with myelofibrosis. The initial dose cohorts were 100, 200, and 300mg orally on days 1–21 of a 28-day cycle. Central and/or peripheral neurotoxicity developed in all patients. Subsequently, patients were treated on lower doses; neurotoxicity was again observed, leading to study termination. Peripheral neuropathy resolved in 50%, and central neurotoxicity in all patients within months after therapy cessation. Myelosuppression was minimal. The terminal half-life of XL019 was approximately 21h, with steady state reached by Day 8. International Working Group defined responses were seen in three (10%) patients.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This phase I study evaluated selective JAK2 inhibitor XL019 in 30 patients with myelofibrosis. The initial dose cohorts were 100, 200, and 300mg orally on days 1–21 of a 28-day cycle. Central and/or peripheral neurotoxicity developed in all patients. Subsequently, patients were treated on lower doses; neurotoxicity was again observed, leading to study termination. Peripheral neuropathy resolved in 50%, and central neurotoxicity in all patients within months after therapy cessation. Myelosuppression was minimal. The terminal half-life of XL019 was approximately 21h, with steady state reached by Day 8. International Working Group defined responses were seen in three (10%) patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Myelofibrosis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Inhibitor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Mutation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">JAK2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">XL019</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tam, Constantine S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wadleigh, Martha</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sokol, Lubomir</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Smith, Catherine C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bui, Lynne A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Song, Chunyan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Clary, Douglas O.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Olszynski, Patrycja</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cortes, Jorge</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kantarjian, Hagop</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shah, Neil P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Li, Danyang ELSEVIER</subfield><subfield code="t">N</subfield><subfield code="d">2019</subfield><subfield code="d">clinical and laboratory studies</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV002185202</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:38</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:316-322</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.leukres.2013.12.006</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-GGO</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">43.12</subfield><subfield code="j">Umweltchemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">43.13</subfield><subfield code="j">Umwelttoxikologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.13</subfield><subfield code="j">Medizinische Ökologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">38</subfield><subfield code="j">2014</subfield><subfield code="e">3</subfield><subfield code="h">316-322</subfield><subfield code="g">7</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Verstovsek, Srdan |
| spellingShingle |
Verstovsek, Srdan ddc 610 ddc 333.7 bkl 43.12 bkl 43.13 bkl 44.13 Elsevier Myelofibrosis Elsevier Inhibitor Elsevier Mutation Elsevier JAK2 Elsevier XL019 Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor |
| authorStr |
Verstovsek, Srdan |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV002185202 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 333 - Economics of land & energy |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 333.7 610 VZ 43.12 bkl 43.13 bkl 44.13 bkl Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor Myelofibrosis Elsevier Inhibitor Elsevier Mutation Elsevier JAK2 Elsevier XL019 Elsevier |
| topic |
ddc 610 ddc 333.7 bkl 43.12 bkl 43.13 bkl 44.13 Elsevier Myelofibrosis Elsevier Inhibitor Elsevier Mutation Elsevier JAK2 Elsevier XL019 |
| topic_unstemmed |
ddc 610 ddc 333.7 bkl 43.12 bkl 43.13 bkl 44.13 Elsevier Myelofibrosis Elsevier Inhibitor Elsevier Mutation Elsevier JAK2 Elsevier XL019 |
| topic_browse |
ddc 610 ddc 333.7 bkl 43.12 bkl 43.13 bkl 44.13 Elsevier Myelofibrosis Elsevier Inhibitor Elsevier Mutation Elsevier JAK2 Elsevier XL019 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
c s t cs cst m w mw l s ls c c s cc ccs l a b la lab c s cs d o c do doc p o po j c jc h k hk n p s np nps |
| hierarchy_parent_title |
N |
| hierarchy_parent_id |
ELV002185202 |
| dewey-tens |
610 - Medicine & health 330 - Economics |
| hierarchy_top_title |
N |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV002185202 |
| title |
Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor |
| ctrlnum |
(DE-627)ELV017314542 (ELSEVIER)S0145-2126(13)00425-6 |
| title_full |
Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor |
| author_sort |
Verstovsek, Srdan |
| journal |
N |
| journalStr |
N |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 300 - Social sciences |
| recordtype |
marc |
| publishDateSort |
2014 |
| contenttype_str_mv |
zzz |
| container_start_page |
316 |
| author_browse |
Verstovsek, Srdan |
| container_volume |
38 |
| physical |
7 |
| class |
610 610 DE-600 333.7 610 VZ 43.12 bkl 43.13 bkl 44.13 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Verstovsek, Srdan |
| doi_str_mv |
10.1016/j.leukres.2013.12.006 |
| dewey-full |
610 333.7 |
| title_sort |
phase i evaluation of xl019, an oral, potent, and selective jak2 inhibitor |
| title_auth |
Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor |
| abstract |
This phase I study evaluated selective JAK2 inhibitor XL019 in 30 patients with myelofibrosis. The initial dose cohorts were 100, 200, and 300mg orally on days 1–21 of a 28-day cycle. Central and/or peripheral neurotoxicity developed in all patients. Subsequently, patients were treated on lower doses; neurotoxicity was again observed, leading to study termination. Peripheral neuropathy resolved in 50%, and central neurotoxicity in all patients within months after therapy cessation. Myelosuppression was minimal. The terminal half-life of XL019 was approximately 21h, with steady state reached by Day 8. International Working Group defined responses were seen in three (10%) patients. |
| abstractGer |
This phase I study evaluated selective JAK2 inhibitor XL019 in 30 patients with myelofibrosis. The initial dose cohorts were 100, 200, and 300mg orally on days 1–21 of a 28-day cycle. Central and/or peripheral neurotoxicity developed in all patients. Subsequently, patients were treated on lower doses; neurotoxicity was again observed, leading to study termination. Peripheral neuropathy resolved in 50%, and central neurotoxicity in all patients within months after therapy cessation. Myelosuppression was minimal. The terminal half-life of XL019 was approximately 21h, with steady state reached by Day 8. International Working Group defined responses were seen in three (10%) patients. |
| abstract_unstemmed |
This phase I study evaluated selective JAK2 inhibitor XL019 in 30 patients with myelofibrosis. The initial dose cohorts were 100, 200, and 300mg orally on days 1–21 of a 28-day cycle. Central and/or peripheral neurotoxicity developed in all patients. Subsequently, patients were treated on lower doses; neurotoxicity was again observed, leading to study termination. Peripheral neuropathy resolved in 50%, and central neurotoxicity in all patients within months after therapy cessation. Myelosuppression was minimal. The terminal half-life of XL019 was approximately 21h, with steady state reached by Day 8. International Working Group defined responses were seen in three (10%) patients. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA SSG-OPC-GGO |
| container_issue |
3 |
| title_short |
Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor |
| url |
https://doi.org/10.1016/j.leukres.2013.12.006 |
| remote_bool |
true |
| author2 |
Tam, Constantine S. Wadleigh, Martha Sokol, Lubomir Smith, Catherine C. Bui, Lynne A. Song, Chunyan Clary, Douglas O. Olszynski, Patrycja Cortes, Jorge Kantarjian, Hagop Shah, Neil P. |
| author2Str |
Tam, Constantine S. Wadleigh, Martha Sokol, Lubomir Smith, Catherine C. Bui, Lynne A. Song, Chunyan Clary, Douglas O. Olszynski, Patrycja Cortes, Jorge Kantarjian, Hagop Shah, Neil P. |
| ppnlink |
ELV002185202 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.leukres.2013.12.006 |
| up_date |
2024-07-06T21:40:34.582Z |
| _version_ |
1803867426214903808 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV017314542</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625122028.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2014 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.leukres.2013.12.006</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2014003000025.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV017314542</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0145-2126(13)00425-6</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">333.7</subfield><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">43.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">43.13</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.13</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Verstovsek, Srdan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2014transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This phase I study evaluated selective JAK2 inhibitor XL019 in 30 patients with myelofibrosis. The initial dose cohorts were 100, 200, and 300mg orally on days 1–21 of a 28-day cycle. Central and/or peripheral neurotoxicity developed in all patients. Subsequently, patients were treated on lower doses; neurotoxicity was again observed, leading to study termination. Peripheral neuropathy resolved in 50%, and central neurotoxicity in all patients within months after therapy cessation. Myelosuppression was minimal. The terminal half-life of XL019 was approximately 21h, with steady state reached by Day 8. International Working Group defined responses were seen in three (10%) patients.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This phase I study evaluated selective JAK2 inhibitor XL019 in 30 patients with myelofibrosis. The initial dose cohorts were 100, 200, and 300mg orally on days 1–21 of a 28-day cycle. Central and/or peripheral neurotoxicity developed in all patients. Subsequently, patients were treated on lower doses; neurotoxicity was again observed, leading to study termination. Peripheral neuropathy resolved in 50%, and central neurotoxicity in all patients within months after therapy cessation. Myelosuppression was minimal. The terminal half-life of XL019 was approximately 21h, with steady state reached by Day 8. International Working Group defined responses were seen in three (10%) patients.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Myelofibrosis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Inhibitor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Mutation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">JAK2</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">XL019</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tam, Constantine S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Wadleigh, Martha</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Sokol, Lubomir</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Smith, Catherine C.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bui, Lynne A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Song, Chunyan</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Clary, Douglas O.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Olszynski, Patrycja</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cortes, Jorge</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kantarjian, Hagop</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shah, Neil P.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Li, Danyang ELSEVIER</subfield><subfield code="t">N</subfield><subfield code="d">2019</subfield><subfield code="d">clinical and laboratory studies</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV002185202</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:38</subfield><subfield code="g">year:2014</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:316-322</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.leukres.2013.12.006</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OPC-GGO</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">43.12</subfield><subfield code="j">Umweltchemie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">43.13</subfield><subfield code="j">Umwelttoxikologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.13</subfield><subfield code="j">Medizinische Ökologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">38</subfield><subfield code="j">2014</subfield><subfield code="e">3</subfield><subfield code="h">316-322</subfield><subfield code="g">7</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.3996487 |